Pharma Pioneer

Roche's Alzheimer's Drug Shows Promise in Mid-Stage Trials

19 May 2024
2 min read

Roche, a pharmaceutical company, has recently announced at an online investor event that their experimental drug for Alzheimer's disease, trontinemab, has shown positive results in a Phase Ib/IIa clinical trial. The drug, an investigational monoclonal antibody, is designed to target amyloid-beta, a protein associated with Alzheimer's. The study, which was led by Azad Bonni, Roche's senior vice president, demonstrated significant reduction in amyloid plaques, a key characteristic of the disease.
Trontinemab was developed using Roche's Brainshuttle technology, which allows the drug to penetrate the blood-brain barrier and achieve better distribution in the brain. The clinical trial was a dose-escalation study involving four groups of patients receiving increasing doses of the drug or a placebo. At the lowest dose of 0.2 mg/kg, amyloid levels were reduced by 20 centiloid units on average, compared to a 5-unit reduction in the placebo group. The highest dose of 3.6 mg/kg, while lacking 28-week data, showed a substantial reduction in amyloid plaques at 12 weeks, with most patients falling below the threshold for amyloid positivity.
The drug was found to be safe and well-tolerated, with only two cases of adverse effects related to amyloid-related imaging abnormalities (ARIA). These incidents were observed in patients receiving the second-highest dose. The positive findings for trontinemab come after Roche's previous setbacks with other Alzheimer's drugs, including crenezumab, which failed to meet its objectives in Phase III trials in 2022, and ganenterumab, which did not meet its primary endpoints in 2022 studies.
In addition to the Alzheimer's research, Roche also presented long-term data on prasinezumab, another drug candidate for Parkinson's disease, which showed potential in slowing motor progression. However, the company noted that these results are preliminary and require further validation through independent trials. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Clearmind Secures Approval for Psychedelic AUD Clinical Trial
Pharma Pioneer
2 min read
Clearmind Secures Approval for Psychedelic AUD Clinical Trial
19 May 2024
The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).
Read →
OpRegen® Phase 1/2a 24-Month Data to Highlight 2024 Retinal Therapy Summit
Pharma Pioneer
3 min read
OpRegen® Phase 1/2a 24-Month Data to Highlight 2024 Retinal Therapy Summit
19 May 2024
Lineage Cell Therapeutics, has announced the upcoming presentation of two-year outcomes from a Phase 1/2a study of RG6501, also known as OpRegen.
Read →
Atsena Initiates Dosing in Phase I/II XLRS Gene Therapy Trial's Second Cohort
Pharma Pioneer
2 min read
Atsena Initiates Dosing in Phase I/II XLRS Gene Therapy Trial's Second Cohort
19 May 2024
In Durham, N.C., Atsena Therapeutics announced that the second group in their LIGHTHOUSE study has started receiving doses of ATSN-201.
Read →
Ocugen Completes Dosing in Phase 1/2 GA Trial's Cohort 1 with OCU410
Pharma Pioneer
3 min read
Ocugen Completes Dosing in Phase 1/2 GA Trial's Cohort 1 with OCU410
19 May 2024
Biotechnology firm Ocugen, Inc. has announced the completion of dosing for the initial group in its Phase 1/2 clinical trial for OCU410.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.